Day: 9. April 2018

The platform is under the RIKEN BioResource Research Center (BRC). It will develop fundamental technology for drug discovery and aim for commercialization, as a bridge between academia and industry with a focus on iPS cell technology. RIKEN news release, April 9, 2018

Takara Bio has announced on April 9 that two gene therapeutic agents for T cell therapy, NY-ESO-1 · siTCRTM, and NY-ESO- (TBI-1301, TBI-1301-A), and a CART cell product, CD 19 · CAR (TBI-1501), a chimeric antigen receptor transgenic T cell (CART) therapy targeting CD 19, jointly developed by both companies, will be exclusively sold by […]